In vitro and in vivo evaluation of osteoinductivity and bone fusion ability of an activin a/BMP2 chimera (AB204): a comparison study between AB204 and rhBMP-2

Growth Factors. 2017 Dec;35(6):249-258. doi: 10.1080/08977194.2018.1459597. Epub 2018 Apr 13.

Abstract

This study compared osteoinductivity and osteogenic capacity between AB204 and rhBMP-2 using hMSCs in vitro and a beagle's posterolateral spinal fusion model. Cultured hMSCs were treated with AB204 or rhBMP-2 with low to high doses. Three male beagles were performed posterolateral spinal fusion with biphasic calcium phosphate (2 ml) + AB204 or rhBMP-2 (20, 50 or 200 µg). They were euthanized after 8 weeks. The fusion rate and bone formation of spine samples were examined. AB204 had higher alkaline phosphatase activity, mineralization and osteogenic-related gene expression than rhBMP-2. Fusion rates in all rhBMP-2 groups were 0. They were 100% for 50 μg and 200 μg AB204 groups. Therefore, AB204 showed higher osteogenicity than rhBMP-2. It could be a better bone graft substitute.

Keywords: AB204; Osteoinduction; activin; posterolateral fusion; rhBMP-2.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaline Phosphatase / metabolism
  • Animals
  • Bone Morphogenetic Protein 2 / administration & dosage
  • Bone Morphogenetic Protein 2 / adverse effects
  • Bone Morphogenetic Protein 2 / therapeutic use*
  • Bone Regeneration
  • Calcium Phosphates / administration & dosage
  • Calcium Phosphates / therapeutic use
  • Cell Line
  • Dogs
  • Humans
  • Male
  • Osteogenesis*
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use*
  • Spinal Fusion / methods*

Substances

  • AB204
  • Bone Morphogenetic Protein 2
  • Calcium Phosphates
  • Recombinant Fusion Proteins
  • calcium phosphate
  • Alkaline Phosphatase